SYRE
HealthcareSpyre Therapeutics, Inc.
$29.96
$-0.62 (-2.03%)
Jan 5, 2026
Price History (1Y)
Analysis
Spyre Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $2.32 billion and approximately 95 employees. The financial health of Spyre Therapeutics, Inc. is characterized by significant losses, with net income totaling -$118,381,000 over the trailing twelve months. The company's profitability metrics are uniformly zero, indicating no gross margin, operating margin, or profit margin during this period. Return on Equity (ROE) and Return on Assets (ROA) are also negative at -38.1% and -30.2%, respectively. The balance sheet is notable for its substantial cash position of $486.20 million. The valuation context for Spyre Therapeutics, Inc. features a forward P/E ratio of -10.78, which suggests significant losses relative to expectations. The company's price-to-book ratio stands at 6.05, while the current ratio is 10.90. Beta is reported as 3.18, indicating high volatility relative to the market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $2.32B
- P/E Ratio
- N/A
- 52-Week High
- $35.31
- 52-Week Low
- $10.91
- Avg Volume
- 958.87K
- Beta
- 3.18
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 95